A Pilot Study on the Effect of Angiotensin Receptor Blockers on Platelet Aggregation in Hypertensive Patients- A Prospective Observational Study

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2017 Jan 5

PMID 28050394

Citations 3

Authors

Arun Suresh

Narendranath Sanji

Pallavi Mahadeva Kamath

Srinivas Lokikere Devendrappa

Shashikala Gowdara Hanumanthareddy

Imran Maniyar

Suresh Surappla Rudrappa

Affiliations

Soon will be listed here.

Abstract

Introduction: Thrombosis is an invariable component contributing to cardiovascular events in patients with hypertension. One of the risk factors of cardiovascular disease is increased platelet activity. One among the widely used antihypertensive agents are Angiotensin II type 1 Receptor Blockers (ARBs). Even though there are many studies involving antihypertensive agents, their antithrombotic properties remain elusive and not fully characterized.

Aim: To evaluate the anti-aggregatory effect of ARBs on platelets in-vivo.

Materials And Methods: A total of 60 subjects were included in this observational pilot study conducted in the medicine out patient department of JJM Hospital, Davanagere, Karnataka, India. Among them, 30 patients with essential hypertension attending Medicine OPD of a tertiary care hospital, who were on ARB for at least one month, were enrolled into study group. The control group consisted of 30 normotensive subjects who were not on any drug affecting platelet function. The Bleeding Time (BT) was evaluated for both the groups using Duke method of BT estimation. Data was analysed using SPSS software version 20. The test group was compared with control group using student's unpaired t-test.

Results: The mean BT of study group was 2.488 minutes ± 0.0361 Standard Error of Mean (SEM) and that of control group was 1.998 minutes ± 0.0362 SEM. The result was statistically significant (p<0.001). The average duration of treatment was 2.933 years.

Conclusion: ARB have antiplatelet activity. Increase in BT in ARB group when compared with that of control group is a reflection of antiplatelet activity.

Citing Articles

Laboratory medicine in arterial hypertension.

Aralica M, Supak-Smolcic V, Honovic L, Franin L, Sonjic P, Simac M Biochem Med (Zagreb). 2023; 33(1):010501.

PMID: 36817852 PMC: 9927727. DOI: 10.11613/BM.2023.010501.

Large-Scale Profiling on lncRNAs in Human Platelets: Correlation with Platelet Reactivity.

Sun Y, Liu R, Xia X, Xing L, Jiang J, Bian W Cells. 2022; 11(14).

PMID: 35883699 PMC: 9319970. DOI: 10.3390/cells11142256.

Angiotensin II-induced Hypertension is Reduced by Deficiency of P-selectin Glycoprotein Ligand-1.

Wang Q, Wang H, Wang J, Venugopal J, Kleiman K, Guo C Sci Rep. 2018; 8(1):3223.

PMID: 29459637 PMC: 5818646. DOI: 10.1038/s41598-018-21588-3.

References

Aukrust P, Damas J, Solum N . Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?. J Am Coll Cardiol. 2004; 43(12):2326-8. DOI: 10.1016/j.jacc.2004.03.023. View

Sakamoto T, Kudoh T, Sakamoto K, Matsui K, Ogawa H . Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study. Hypertens Res. 2014; 37(6):513-8. DOI: 10.1038/hr.2014.22. View

Monton M, Jimenez A, Nunez A, Farre J, Gomez J, Zalba L . Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol. 2000; 35(6):906-13. DOI: 10.1097/00005344-200006000-00012. View

Schwemmer M, Sommer O, Bassenge E . Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther. 2002; 15(4):301-7. DOI: 10.1023/a:1012750430056. View

Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis D, Diodati J . A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007; 28(14):1702-8. DOI: 10.1093/eurheartj/ehm226. View

Ripley E, Hirsch A . Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?. Int J Nephrol Renovasc Dis. 2011; 3:93-8. PMC: 3108782. DOI: 10.2147/ijnrd.s7038. View

Monton M, Rodriguez-Feo J, Jimenez A, Gonzalez-Fernandez F, Rico L, Garcia R . Effect of losartan on human platelet activation. J Hypertens. 1999; 17(3):447-52. DOI: 10.1097/00004872-199917030-00019. View

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

Whitehead A, Julious S, Cooper C, Campbell M . Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2015; 25(3):1057-73. PMC: 4876429. DOI: 10.1177/0962280215588241. View

10.

Gitt A, Bramlage P, Potthoff S, Baumgart P, Mahfoud F, Buhck H . Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord. 2016; 16:56. PMC: 4784379. DOI: 10.1186/s12872-016-0222-6. View

11.

Maleki A, Roohafza H, Rashidi N, Aliyari F, Ghanavati R, Foroughi S . Determination of normal range of bleeding time in rural and urban residents of Borujerd, Iran: A pilot study. ARYA Atheroscler. 2013; 8(3):136-42. PMC: 3557001. View

12.

Sato Y, Fujii S, Imagawa S, Ohmura K, Ohmura Y, Andoh Y . Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb. 2007; 14(1):31-5. DOI: 10.5551/jat.14.31. View

13.

Preston R, Jy W, Jimenez J, Mauro L, Horstman L, Valle M . Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003; 41(2):211-7. DOI: 10.1161/01.hyp.0000049760.15764.2d. View

14.

Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T . Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002; 40(4):521-7. DOI: 10.1161/01.hyp.0000034745.98129.ec. View